Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Neelam Mukherjee"'
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/02042523473c4ad8abec7197b58e8218
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
There is a continuous cycle of activation and contraction in the immune response against pathogens and other threats to human health in life. This intrinsic yin-yang of the immune response ensures that inflammatory processes can be appropriately cont
Externí odkaz:
https://doaj.org/article/898846bccb594ddbbac8ae4cff526263
Autor:
Neelam Mukherjee, Niannian Ji, Xi Tan, Chun‐Liang Chen, Onika D. V. Noel, Maria Rodriguez‐Padron, Chun‐Lin Lin, David G. Alonzo, Tim H. Huang, Robert S. Svatek
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8970-8980 (2023)
Abstract Background Bladder tumor‐infiltrating CD56bright NK cells are more tumor cytotoxic than their CD56dim counterparts. Identification of NK cell subsets is labor‐intensive and has limited utility in the clinical setting. Here, we sought to
Externí odkaz:
https://doaj.org/article/98c2847b0a794068bb24d70f5e7170de
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/5080ab3da4ac47818fbbb9c067ebe123
Autor:
Neelam Mukherjee, Niannian Ji, Xi Tan, Chun‐Lin Lin, Emily Rios, Chun‐Liang Chen, Tim Huang, Robert S. Svatek
Publikováno v:
Cancer Medicine, Vol 10, Iss 20, Pp 7101-7110 (2021)
Abstract Purpose Human innate lymphoid cells (hILCs) are lineage‐negative immune cells that do not express rearranged adaptive antigen receptors. Natural killer (NK) cells are hILCs that contribute to cancer defense. The role of non‐NK hILCs in c
Externí odkaz:
https://doaj.org/article/cae3864709ee485294470a135cf09666
Autor:
Yilun Deng, Aravind Kancharla, Myrna Garcia, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Tyler J Curiel, Robert S Svatek, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Chenghao Zhang, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in
Externí odkaz:
https://doaj.org/article/2a231be16e8747f5b3befb1e7bde6cde
Autor:
Niannian Ji, Neelam Mukherjee, Tyler J Curiel, Ryan M Reyes, Jonathan Gelfond, Martin Javors, Joshua J. Meeks, David J McConkey, Zhen-Ju Shu, Chethan Ramamurthy, Ryan Dennett, Robert S Svatek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the
Externí odkaz:
https://doaj.org/article/8727334813974223b8ab1c8584e1818e
Autor:
Ryan M Reyes, Chenghao Zhang, Yilun Deng, Niannian Ji, Neelam Mukherjee, Alvaro S Padron, Curtis A Clark, Robert S Svatek, Tyler J Curiel
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Bladder cancer (BC) and melanoma are amenable to immune checkpoint blockade (ICB) therapy, yet most patients with advanced/metastatic disease do not respond. CD122-targeted interleukin (IL)-2 can improve ICB efficacy, but mechanisms are unclear. We t
Externí odkaz:
https://doaj.org/article/6f57b3a6ecf3451ead7b6bb61c301abc
Autor:
Tyler Curiel, Yilun Deng, Ryan Reyes, Aravind Kancharla, Myrna Garcia, Harshita Gupta, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Anand Kornepati, Robert Svatek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/bbced6c544ac43fdab14ee9c11f0f945
Autor:
Niannian Ji, Neelam Mukherjee, Edwin E. Morales, Maggie E. Tomasini, Vincent Hurez, Tyler J. Curiel, Getahun Abate, Dan F. Hoft, Xiang-Ru Zhao, Jon Gelfond, Sourindra Maiti, Laurence J.N. Cooper, Robert S. Svatek
Publikováno v:
OncoImmunology, Vol 8, Iss 8 (2019)
Background: Intravesical bacillus Calmette-Guérin (BCG) is the gold standard immunologic agent for treating patients with high-grade non-muscle invasive bladder cancer (NMIBC). Nevertheless, relapse rates remain high and BCG unresponsive NMIBC often
Externí odkaz:
https://doaj.org/article/6d77a692e2c14502a3870a79efe0d2ef